Baseline patient demographics and clinical characteristics
| CP-870,893 Dose cohort | |||
|---|---|---|---|
| 0.1 mg/kg (n = 3) | 0.2 mg/kg (n = 6) | MTD expansion 0.2 mg/kg (n = 13) | |
| Characteristic | n (%) | n (%) | n (%) |
| Age, y | |||
| Median | 59 | 59 | |
| Range | 57–72 | 40–81 | |
| Sex | |||
| Male | 2 (67) | 3 (50) | 9 (69) |
| Female | 1 (33) | 3 (50) | 4 (31) |
| Race/ethnicity | |||
| White | 0 (0) | 5 (83) | 11 (84) |
| Black | 3 (100) | 1 (17) | 1 (8) |
| Asian | 0 (0) | 0 (0) | 1 (8) |
| ECOG PS | |||
| 0 | 2 (67) | 5 (83) | 2 (15) |
| 1 | 1 (33) | 1 (17) | 11 (85) |
| Extent of disease | |||
| Locally advanced | 0 (0) | 0 (0) | 2 (15) |
| Metastatic | 3 (100) | 6 (100) | 11 (85) |
| Location of primary | |||
| Head | 2 (67) | 2 (33) | 4 (31) |
| Body or tail | 1 (33) | 2 (33) | 9 (69) |
| Not reported | 0 (0) | 2 (33) | 0 (0) |
| Site of metastases | |||
| Liver | 3 (100) | 5 (83) | 10 (77) |
| Lung | 0 (0) | 2 (33) | 0 (0) |
| Peritoneal | 0 (0) | 0 (0) | 3 (23) |
| Skeleton | 0 (0) | 2 (33) | 0 (0) |
| Other | 0 (0) | 0 (0) | 1 (8) |
| Prior radiotherapies | |||
| No | 3 (100) | 6 (100) | 11 (84) |
| Yes | 0 (0) | 0 (0) | 1 (8) |
| Not reported | 0 (0) | 0 (0) | 1 (8) |